Top Core and Group Health Stories
Rising diabetes rates drive pharma opportunities as GLP-1s shake up treatment
By Kristen SmithbergGlobal prevalence climbs, boosting demand for insulin, devices and new therapies like Mounjaro and Ozempic.
News, insight, and analysis from industry experts to help benefits brokers, consultants and advisors make their way through the tumultuous reformed health care marketplace. Content will help them grow their practices by focusing on a wide range of products, discussing new sales and marketing strategies and highlighting innovative and disruptive brokers who are forging a new path in today's benefits marketplace.
Global prevalence climbs, boosting demand for insulin, devices and new therapies like Mounjaro and Ozempic.